

**Company Number: 680810**

**IX Biopharma Europe Limited**  
**Abridged Financial Statements**  
**for the financial year ended 30 June 2025**

## **IX Biopharma Europe Limited CONTENTS**

	<b>Page</b>
Directors' Responsibilities Statement	3
Independent Auditor's Special Report to the Directors	4 - 6
Statement of Financial Position	7
Statement of Changes in Equity	8
Notes to the Financial Statements	9 - 14

# IX Biopharma Europe Limited DIRECTORS' RESPONSIBILITIES STATEMENT

for the financial year ended 30 June 2025

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable Irish law and regulations.


Irish company law requires the directors to prepare financial statements for each financial year. Under that law, the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard, issued by the Financial Reporting Council. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.


The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Directors' Report comply with the Companies Act 2014 and enable the financial statements to be readily and properly audited. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

## Signed on behalf of the board

Signed by:  
  
5FE82A4CC0C94A4...

**Sien Lup Chew**  
Director

Date: Mar-02-2026

DocuSigned by:  
  
48840322D66C479...

**Janakan Krishnarajah**  
Director

Date: Mar-02-2026

# **INDEPENDENT AUDITOR'S SPECIAL REPORT TO THE DIRECTORS OF IX BIOPHARMA EUROPE LIMITED**

## **pursuant to section 356(1) and 356(2) of the Companies Act 2014**

### **Opinion**

In our opinion the directors are entitled under section 352 of the Companies Act 2014 to annex the abridged financial statements to the annual return of IX Biopharma Europe Limited ('the company') and those abridged financial statements have been properly prepared pursuant to the provisions of section 353 of that Act (exemptions available to small companies).

### **Basis of opinion**

We have examined :

- (i) the abridged financial statements for the financial year ended 30 June 2025 on pages 7 to 14 which the directors of IX Biopharma Europe Limited propose to annex to the annual return of the company; and
- (ii) the financial statements to be laid before the Annual General Meeting, which form the basis for those abridged financial statements.

The scope of our work for the purpose of this report was limited to confirming that the directors are entitled to annex abridged financial statements to the annual return and that those abridged financial statements have been properly prepared, pursuant to section 353 of the Companies Act 2014, from the financial statements to be laid before the Annual General Meeting.

### **Respective responsibilities of directors and auditors**

It is your responsibility to prepare abridged financial statements which comply with section 352 of the Companies Act 2014. It is our responsibility to form an independent opinion that the directors are entitled under section 352 of the Companies Act 2014 to annex abridged financial statements to the annual return of the company and that those abridged financial statements have been properly prepared pursuant to sections 352 and 353 of that Act and to report our opinion to you.

This report is made solely to the company's directors, as a body, in accordance with section 356(2) of the Companies Act 2014. Our work has been undertaken so that we might state to the directors those matters we are required to state to them in our report under section 356(2) of the Companies Act 2014 and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the directors for our work, for this report, or for the opinions we have formed.

### **Other Information required by the Companies Act 2014**

On Date: March 2, 2016 we reported to the members on the company's financial statements for the financial year ended 30 June 2025 and our report was as follows:

### **"Report on the audit of the financial statements**

#### **Opinion**

We have audited the financial statements of IX Biopharma Europe Limited ('the company') for the financial year ended 30 June 2025 which comprise the Income Statement, the Statement of Financial Position, the Statement of Changes in Equity and the related notes to the financial statements, including the summary of significant accounting policies set out in note 2. The financial reporting framework that has been applied in their preparation is Irish Law and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", issued in the United Kingdom by the Financial Reporting Council, applying Section 1A of that Standard.

In our opinion the financial statements:

- give a true and fair view of the assets, liabilities and financial position of the company as at 30 June 2025 and of its loss for the financial year then ended;
- have been properly prepared in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard; and
- have been properly prepared in accordance with the requirements of the Companies Act 2014.

#### **Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing (Ireland) (ISAs (Ireland)) and applicable law. Our responsibilities under those standards are described below in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of financial statements in Ireland, including the Ethical Standard for Auditors (Ireland) issued by the Irish Auditing and Accounting Supervisory Authority (IAASA), and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

# **INDEPENDENT AUDITOR'S SPECIAL REPORT TO THE DIRECTORS OF IX BIOPHARMA EUROPE LIMITED**

## **pursuant to section 356(1) and 356(2) of the Companies Act 2014**

### **Conclusions relating to going concern**

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from the date when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

### **Other Information**

The directors are responsible for the other information. The other information comprises the information included in the annual report other than the financial statements and our Auditor's Report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

### **Opinions on other matters prescribed by the Companies Act 2014**

In our opinion, based on the work undertaken in the course of the audit, we report that:

- the information given in the Directors' Report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Directors' Report has been prepared in accordance with applicable legal requirements.

We have obtained all the information and explanations which, to the best of our knowledge and belief, are necessary for the purposes of our audit.

In our opinion the accounting records of the company were sufficient to permit the financial statements to be readily and properly audited and the financial statements are in agreement with the accounting records.

### **Matters on which we are required to report by exception**

Based on the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified any material misstatements in the directors' report.

The Companies Act 2014 requires us to report to you if, in our opinion, the requirements of any of sections 305 to 312 of the Act, which relate to disclosures of directors' remuneration and transactions are not complied with by the Company. We have nothing to report in this regard.

### **Respective responsibilities**

#### **Responsibilities of directors for the financial statements**

As explained more fully in the Directors' Responsibilities Statement set out on page 3, the directors are responsible for the preparation of the financial statements in accordance with the applicable financial reporting framework that give a true and fair view, and for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, if applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the company or to cease operation, or has no realistic alternative but to do so.

# INDEPENDENT AUDITOR'S SPECIAL REPORT TO THE DIRECTORS OF IX BIOPHARMA EUROPE LIMITED

pursuant to section 356(1) and 356(2) of the Companies Act 2014


### Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditor's Report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (Ireland) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on the IAASA's website at: [www.iaasa.ie/wp-content/uploads/2022/10/Description\\_of\\_auditors\\_responsibilities\\_for\\_audit.pdf](http://www.iaasa.ie/wp-content/uploads/2022/10/Description_of_auditors_responsibilities_for_audit.pdf). The description forms part of our Auditor's Report.

### The purpose of our audit work and to whom we owe our responsibilities

Our report is made solely to the company's shareholders, as a body, in accordance with section 391 of the Companies Act 2014. Our audit work has been undertaken so that we might state to the company's shareholders those matters we are required to state to them in an Auditor's Report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume any responsibility to anyone other than the company and the company's shareholders, as a body, for our audit work, for this report, or for the opinions we have formed."



**Helene Cleary**

for and on behalf of

**CLEARY & COMPANY**

Chartered Certified Accountants and Statutory Audit Firm

F8 Nutgrove Office Park

Rathfarnham

Dublin 14

Date: March 2, 2026

We certify that the auditor's report on pages 4 - 6 made pursuant to section 356(1) of the Companies Act 2014 is a true copy of the original.

Signed by:



**Vistra Assurance (Ireland) Limited**

Secretary

Mar-02-2026

Date: \_\_\_\_\_

Signed by:



**Sien Lup Chew**

Director

Mar-02-2026

Date: \_\_\_\_\_

**IX Biopharma Europe Limited**  
**STATEMENT OF FINANCIAL POSITION**  
as at 30 June 2025


	Notes	2025 €	2024 €
<b>Non-Current Assets</b>			
Intangible assets	8	5,177,891	5,793,086
Financial assets	9	47	47
<b>Non-Current Assets</b>		<b>5,177,938</b>	<b>5,793,133</b>
<b>Current Assets</b>			
Debtors	10	94,537	132,973
Cash and cash equivalents		18,000	45,994
		<b>112,537</b>	<b>178,967</b>
<b>Creditors: amounts falling due within one year</b>	11	<b>(2,130,600)</b>	<b>(2,120,522)</b>
<b>Net Current Liabilities</b>		<b>(2,018,063)</b>	<b>(1,941,555)</b>
<b>Total Assets less Current Liabilities</b>		<b>3,159,875</b>	<b>3,851,578</b>
<b>Provisions for liabilities</b>	13	<b>325,166</b>	238,703
<b>Net Assets</b>		<b>3,485,041</b>	<b>4,090,281</b>
<b>Capital and Reserves</b>			
Called up share capital presented as equity		1	1
Retained earnings		3,485,040	4,090,280
<b>Equity attributable to owners of the company</b>		<b>3,485,041</b>	<b>4,090,281</b>


The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard.

We as Directors of IX Biopharma Europe Limited, state that -  
The company has relied on the specified exemption contained in section 352 Companies Act 2014. The company has done so on the grounds that it is entitled to the benefit of that exemption as a small company and confirm that the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014 and the small companies' regime.

Mar-02-2026

Approved by the board on \_\_\_\_\_ and signed on its behalf by:

Signed by:  
  
5FE82A4CC0C94A4...  
**Sien Lup Chew**  
Director

DocuSigned by:  
  
49810322D68C479...  
**Janakan Krishnarajah**  
Director

**IX Biopharma Europe Limited**  
**STATEMENT OF CHANGES IN EQUITY**  
as at 30 June 2025

	<b>Called up share capital €</b>	<b>Retained earnings €</b>	<b>Total €</b>
<b>At 1 July 2023</b>	1	4,860,049	4,860,050
Loss for the financial year	-	(769,769)	(769,769)
<b>At 30 June 2024</b>	1	4,090,280	4,090,281
Loss for the financial year	-	(605,240)	(605,240)
<b>At 30 June 2025</b>	<b>1</b>	<b>3,485,040</b>	<b>3,485,041</b>

# IX Biopharma Europe Limited

## NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 June 2025

### 1. General Information

IX Biopharma Europe Limited is a company limited by shares incorporated in Ireland. The registered number of the company is 680810. The registered office of the company is Block A, George's Quay Plaza, George's Quay, Dublin 2 which is also the principal place of business of the company. The principal activity of the company is to acquire, develop and exploit pharmaceutical products and provide support services to its ultimate parent iX Biopharma Ltd, a company incorporated in Singapore operating in the pharmaceuticals industry.

iX Biopharma Ltd is a listed entity on the Singapore Stock Exchange that develops and manufactures pharmaceutical and nutraceutical products. iX Biopharma Ltd operates under cGMP (Current Good Manufacturing Practice) regulations under the oversight of Therapeutic Goods Administration of Australia. The financial statements have been presented in Euro (€) which is also the functional currency of the company.

### 2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

#### Statement of compliance

The financial statements of the company for the financial year ended 30 June 2025 have been prepared in accordance with the provisions of FRS 102 Section 1A (Small Entities) and the Companies Act 2014.

#### Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" Section 1A, issued by the Financial Reporting Council.

The company qualifies as a small company as defined by section 280A of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Companies Act 2014 and Section 1A of FRS 102.

#### Turnover

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Rendering of services and goods

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:

- the amount of revenue can be measured reliably;
- it is probable that the company will receive the consideration due under the contract;
- the stage of completion of the contract at the end of the reporting period can be measured reliably; and
- the costs incurred and the costs to complete the contract can be measured reliably.

#### Financial Instruments

A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument.

Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Debt instruments are subsequently measured at amortised cost.

Where investments in non-convertible preference shares and non-puttable ordinary shares or preference shares are publicly traded or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value with changes in fair value recognised in profit or loss. All other such investments are subsequently measured at cost less impairment.

## IX Biopharma Europe Limited

# NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 June 2025

Other financial instruments, including derivatives, are initially recognised at fair value, unless payment for an asset is deferred beyond normal business terms or financed at a rate of interest that is not a market rate, in which case the asset is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Other financial instruments are subsequently measured at fair value, with any changes recognised in profit or loss, with the exception of hedging instruments in a designated hedging relationship.

Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately.

For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets or either assessed individually or grouped on the basis of similar credit risk characteristics.

Any reversals of impairment are recognised in profit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.

### Financial Reporting Standard 102 - reduce disclosure exemptions

The company has taken advantage of the following disclosure exemptions for the first time in the current financial period in preparing these financial statements, as permitted by the FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland":

- the requirements of Section 7 Statement of Cash Flows;
- the requirements of Section 33 Related Party Disclosure paragraph 33.7.

This information is included in the consolidated financial statements of iX Biopharma Ltd. as at 30 June 2025 and their financial statements may be obtained from <https://www.ixbiopharma.com/financials/>.

### Intangible assets

#### Trademarks & Licences

Intangible assets are valued at cost less accumulated amortisation.

Amortisation is calculated to write off the cost in equal annual instalments over their estimated useful life of 12 years.

#### Financial assets

Investments held as fixed assets are stated at cost less provision for any permanent diminution in value. Income from other investments together with any related withholding tax is recognised in the Income Statement in the financial year in which it is receivable.

#### Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

#### Cash and cash equivalents

Cash and cash equivalents comprise cash at bank and in hand, demand deposits with banks and other short-term highly liquid investments with original maturities of three months or less and bank overdrafts. In the Statement of Financial Position bank overdrafts are shown within Creditors.

#### Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

## IX Biopharma Europe Limited

# NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 June 2025

### Related parties

For the purposes of these financial statements a party is considered to be related to the company if:

- the party has the ability, directly or indirectly, through one or more intermediaries to control the company or exercise significant influence over the company in making financial and operating policy decisions or has joint control over the company;
- the company and the party are subject to common control;
- the party is an associate of the company or forms part of a joint venture with the company;
- the party is a member of key management personnel of the company or the company's parent, or a close family member of such as an individual, or is an entity under the control, joint control or significant influence of such individuals;
- the party is a close family member of a party referred to above or is an entity under the control or significant influence of such individuals; or
- the party is a post-employment benefit plan which is for the benefit of employees of the company or of any entity that is a related party of the company.

Close family members of an individual are those family members who may be expected to influence, or be influenced by, that individual in their dealings with the company.

### Taxation and deferred taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Statement of Financial Position date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more tax in the future, or a right to pay less tax in the future. Timing differences are temporary differences between the company's taxable profits and its results as stated in the financial statements.

Deferred tax is measured on an undiscounted basis at the tax rates that are anticipated to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the Statement of Financial Position date.

### Foreign currencies

Monetary assets and liabilities denominated in foreign currencies are translated at the rates of exchange ruling at the Statement of Financial Position date. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated at the rates of exchange ruling at the date of the transaction. Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. The resulting exchange differences are dealt with in the Income Statement.

### Ordinary share capital

The ordinary share capital of the company is presented as equity.

### 3. Significant accounting judgements and key sources of estimation uncertainty

The preparation of these financial statements requires management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, income and expenses. Judgements and estimates are continually evaluated and are based on historical experiences and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

The company makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are listed below:

#### Useful Lives of Intangible and Tangible Fixed Assets

Fixed assets represent a significant portion of total assets. The annual depreciation and amortisation charge depends primarily on the estimated lives of each type of asset and, in certain circumstances, estimates of residual values. The directors regularly review these useful lives and change them if necessary to reflect current conditions. In determining these useful lives management consider technological change, patterns of consumption, physical condition and expected economic utilisation of the assets. Changes in the useful lives can have a significant impact on the depreciation and amortisation charge for the financial year.

## IX Biopharma Europe Limited

# NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 June 2025

### Provisions

Provisions are recognised when the entity has a present obligation (legal or constructive) as a result of past event, and it is probable that the entity would be required to settle the probable outflow of resources, and a reliable estimate can be made of the amount of the obligation.

### Going Concern

See Note 4 below.

#### 4. Going concern

The financial statements have been prepared on the going concern basis. In considering the going concern assumption, the directors note the reported loss of €605,240 (2024: €769,769) and net assets of €3,485,041 (2024: €4,090,281).

After making enquiries and reviewing development projections and forecasts and having taken into account of continuous financial supports from the group companies, the directors have a reasonable expectation that the company will have adequate resources to continue in operational existence for a period of not less than 12 months from the date of approval of the financial statements. The company has the full support of the parent company. The directors are not aware of any events likely to occur in the foreseeable future that may impact on the company's ability to continue as a going concern. Accordingly, the directors consider it appropriate to prepare the financial statements on a going concern basis. The financial statements do not include any adjustments that would result if the company were unable to continue as a going concern.

<b>5. Operating loss</b>	<b>2025</b>	<b>2024</b>
	€	€
<b>Operating loss is stated after charging/(crediting):</b>		
Amortisation of intangible assets	<b>615,195</b>	615,195
(Profit)/loss on foreign currencies	<b>(105,244)</b>	12,273
	<u>                    </u>	<u>                    </u>
<b>6. Interest payable and similar expenses</b>	<b>2025</b>	<b>2024</b>
	€	€
Interest	<b>27,498</b>	34,673
	<u>                    </u>	<u>                    </u>
<b>7. Employees</b>		
The company has no employees (2024: None).		
<b>8. Intangible assets</b>	<b>Trademarks &amp; Licences</b>	<b>Total</b>
	€	€
<b>Cost</b>		
At 1 July 2024	<u>7,382,340</u>	<u>7,382,340</u>
At 30 June 2025	<u>7,382,340</u>	<u>7,382,340</u>
<b>Provision for diminution in value</b>		
At 1 July 2024	<u>1,589,254</u>	<u>1,589,254</u>
Charge for financial year	615,195	615,195
At 30 June 2025	<u>2,204,449</u>	<u>2,204,449</u>
<b>Net book value</b>		
At 30 June 2025	<u><b>5,177,891</b></u>	<u><b>5,177,891</b></u>
At 30 June 2024	<u>5,793,086</u>	<u>5,793,086</u>

continued

**IX Biopharma Europe Limited**  
**NOTES TO THE ABRIDGED FINANCIAL STATEMENTS**  
for the financial year ended 30 June 2025

**9. Financial fixed assets**

	Subsidiary undertakings shares	Total
	€	€
<b>Investments</b>		
<b>Cost</b>		
At 30 June 2025	47	47
<b>Net book value</b>		
At 30 June 2025	<u>47</u>	<u>47</u>
At 30 June 2024	<u>47</u>	<u>47</u>

**10. Debtors**

	2025 €	2024 €
Amounts owed by group undertakings	92,545	130,728
Other debtors	1,992	2,051
Prepayments	-	194
	<u>94,537</u>	<u>132,973</u>

All debtor amounts above are due within 12 months.

**11. Creditors**

	2025 €	2024 €
<b>Amounts falling due within one year</b>		
Trade creditors	12,398	19,975
Amounts owed to group undertakings	1,714,712	1,590,710
Taxation	370,847	486,680
Accruals	32,643	23,157
	<u>2,130,600</u>	<u>2,120,522</u>

The repayment terms of trade creditors vary between on demand and thirty days. No interest is payable on trade creditors.

Taxation is subject to the terms of the relevant legislation.

The terms of the accruals are based on the underlying contracts.

Other amounts included within creditors not covered by specific note disclosures are unsecured, interest free and repayable on demand.

**12. Taxation**

The taxation creditors as disclosed in Note 11 above are made of the following amounts:

	2025 €	2024 €
Corporation Tax payable - current	123,384	115,833
Corporation Tax payable - non current	247,463	370,847
	<u>370,847</u>	<u>486,680</u>

On 1 May 2023, the company entered into a phased payment plan to settle all outstanding corporation tax due as above within 5 years. The overdue taxation incurs interest at 8% per annum.

**IX Biopharma Europe Limited**  
**NOTES TO THE ABRIDGED FINANCIAL STATEMENTS**  
for the financial year ended 30 June 2025

**13. Provisions for liabilities**

The amounts provided for deferred taxation are analysed below:

	Losses	Total	Total
	€	2025 €	2024 €
At financial year start	(238,703)	<b>(238,703)</b>	(135,462)
Charged to profit and loss	(86,463)	<b>(86,463)</b>	(103,241)
At financial year end	<u><b>(325,166)</b></u>	<u><b>(325,166)</b></u>	<u>(238,703)</u>

**14. Income Statement**

	2025 €	2024 €
At 1 July 2024	<b>4,090,280</b>	4,860,049
Loss for the financial year	<b>(605,240)</b>	(769,769)
At 30 June 2025	<u><b>3,485,040</b></u>	<u>4,090,280</u>

**15. Capital commitments**

The company had no material capital commitments at the financial year-ended 30 June 2025.

**16. Related party transactions**

The company has availed of the exemption under FRS 102 Section 1A in relation to the disclosure of transactions with group undertakings.

**17. Parent and ultimate parent company**

The company regards iX Biopharma Ltd as its parent and ultimate parent company. The address of iX Biopharma Ltd is 1 Kim Seng Promenade, #14-01 Great World City, (East Tower), 237994, Singapore.

iX Biopharma Ltd. is regarded as both the controlling party and the ultimate controlling party.

**18. Events After the End of the Reporting Period**

There have been no events subsequent to the year end date requiring adjustment to, or disclosure in, the financial statements.

**19. Approval of financial statements**

The financial statements were approved and authorised for issue by the board of directors on Mar-02-2026.